keyword
MENU ▼
Read by QxMD icon Read
search

Tolterodine

keyword
https://www.readbyqxmd.com/read/28265325/overactive-bladder-in-children
#1
REVIEW
Sophie Ramsay, Stéphane Bolduc
Overactive bladder (OAB) is a highly prevalent disorder in the pediatric population. This condition is especially troublesome for pediatric patients and their families when associated with incontinence, since it negatively affects self-esteem and impairs children's development. From the patient's perspective, urgency and urge incontinence can have a significant impact, negatively affecting their quality of life. For a therapy to have true benefit, changes must not only be statistically significant, but must also be perceived as meaningful by the patient...
January 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28199076/the-effect-of-extended-release-tolterodine-used-for-overactive-bladder-treatment-on-female-sexual-function
#2
Athanasios Zachariou, Maria Filiponi
INTRODUCTION: Overactive bladder (OAB) is a common condition, especially in middle aged women, requiring long term therapy with anticholinergics to maintain symptoms relief. The aim of the study was to determine the effect of tolterodine extended release (ER) used for OAB treatment on the sexual function of women. MATERIALS AND METHODS: Between August 2010 and August 2014, 220 women with confirmed OAB, attended Urogynecology Outpatient Clinic and were prospectively enrolled in this study...
February 15, 2017: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/28196724/persistence-and-adherence-with-mirabegron-versus-antimuscarinic-agents-in-patients-with-overactive-bladder-a-retrospective-observational-study-in-uk-clinical-practice
#3
Christopher R Chapple, Jameel Nazir, Zalmai Hakimi, Sally Bowditch, Francis Fatoye, Florent Guelfucci, Amine Khemiri, Emad Siddiqui, Adrian Wagg
BACKGROUND: Persistence with antimuscarinic therapy in overactive bladder (OAB) is poor, but may be different for mirabegron, a β3-adrenoceptor agonist with a different adverse event profile. OBJECTIVE: To compare persistence and adherence with mirabegron versus tolterodine extended release (ER) and other antimuscarinics in routine clinical practice over a 12-mo period. DESIGN, SETTING, AND PARTICIPANTS: Retrospective, longitudinal, observational study of anonymised data from the UK Clinical Practice Research Datalink GOLD database...
February 11, 2017: European Urology
https://www.readbyqxmd.com/read/28163191/csahi-study-detection-of-drug-induced-ion-channel-receptor-responses-qt-prolongation-and-arrhythmia-using-multi-electrode-arrays-in-combination-with-human-induced-pluripotent-stem-cell-derived-cardiomyocytes
#4
Takashi Kitaguchi, Yuta Moriyama, Tomohiko Taniguchi, Sanae Maeda, Hiroyuki Ando, Takaaki Uda, Koji Otabe, Masao Oguchi, Shigekazu Shimizu, Hiroyuki Saito, Atsushi Toratani, Mahoko Asayama, Wataru Yamamoto, Emi Matsumoto, Daisuke Saji, Hiroki Ohnaka, Norimasa Miyamoto
INTRODUCTION: The use of multi-electrode arrays (MEA) in combination with human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provides a promising method to predict comprehensive cardiotoxicity, including drug-induced QT prolongation and arrhythmia. We previously demonstrated that MEA in combination with hiPSC-CMs could provide a generalizable platform by using 7 reference drugs at 10 testing facilities. Using this approach, we evaluated responses to reference drugs that modulate a range of cardiac ion currents and have a range of arrhythmogenic effects...
February 2, 2017: Journal of Pharmacological and Toxicological Methods
https://www.readbyqxmd.com/read/28150133/impact-of-age-and-polytherapy-on-fingolimod-induced-bradycardia-a-preclinical-study
#5
Christian Ritter, Martin K R Svačina, Ilja Bobylev, Abhijeet Joshi, Toni Schneider, Helmar C Lehmann
Fingolimod is a an oral disease modifying drug for relapsing remitting multiple sclerosis (MS) preventing egress of B and T cells from lymph nodes. Relevant first dose adverse events include bradycardia and atrioventricular conduction slowing. Cardiac side effects of fingolimod and combinational pharmacotherapy including duloxetine and tolterodine were monitored in mice of different age using implantable ECG telemetric systems. Cardiac tissue was assessed for S1P-receptor subtype (1 and 3), and for GIRK1 expression...
February 1, 2017: Journal of Neuroimmune Pharmacology: the Official Journal of the Society on NeuroImmune Pharmacology
https://www.readbyqxmd.com/read/28120444/histopathologic-and-urodynamic-effects-of-the-anticholinergic-drugs-oxybutynin-tolterodine-and-trospium-on-the-bladder
#6
Seyfettin Orgen, Hasan Deliktas, Hayrettin Sahin, Abdullah Gedik, Yusuf Nergis
OBJECTIVES: This study aimed to evaluate the effects of intravesical instillation of the anticholinergic drugs oxybutynin, tolterodine, and trospium on bladder capacity and histopathological changes in the bladder mucosa. METHODS: The study included 20 male New Zealand white rabbits that were randomly allocated to four groups of five. In the oxybutynin, tolterodine, and trospium groups, the drugs used were 1 mg/kg of crushed tablet mixed with 5 mL of saline, instilled intravesically once per day for 4 weeks...
January 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28087463/effect-of-22-cyp2d6-variants-found-in-the-chinese-population-on-tolterodine-metabolism-in%C3%A2-vitro
#7
Hao Wang, Da-Peng Dai, Peng Sun, Li-Ping Xu, Bing-Qing Liang, Jian-Ping Cai, Guo-Xin Hu
Cytochrome P450 2D6 (CYP2D6) is an important member of the cytochrome P450 enzyme superfamily. We recently identified 22 novel variants in the Chinese population using PCR and bidirectional sequencing methods. The aim of this study is to characterize the enzymatic activity of these variants and their effects on the metabolism of the antimuscarinic drug tolterodine in vitro. A baculovirus-mediated expression system was used to express wild-type CYP2D6 and 24 variants (CYP2D6*2, CYP2D6*10, and 22 novel CYP2D6 variants) at high levels...
February 25, 2017: Chemico-biological Interactions
https://www.readbyqxmd.com/read/28025920/impact-of-overactive-bladder-step-therapy-policies-on-medication-utilization-and-expenditures-among-treated-medicare-members
#8
Ibrahim M Abbass, Eleanor O Caplan, Daniel B Ng, Rita Kristy, Carol R Schermer, Pamela Bradt, Jenna M Collins, Wai Man Maria Chan, Brandon T Suehs
BACKGROUND: The impact of formulary management strategies on utilization and expenditures in overactive bladder (OAB) treatment has not been extensively investigated. In 2013, step therapy (ST) policies for 2 branded OAB treatments, mirabegron and fesoterodine, were removed from Humana Medicare Advantage Prescription Drug (MAPD) plans and Medicare prescription drug plans (PDP), allowing for an examination of the effect of ST policies on OAB medication use patterns and costs. OBJECTIVE: To assess the impact of removal of formulary restriction policies for mirabegron and fesoterodine on medication utilization patterns and costs associated with OAB treatment in Medicare patients...
January 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27965369/pharmacological-characterization-of-a-novel-beta3-adrenergic-agonist-vibegron-evaluation-of-anti-muscarinic-receptor-selectivity-for-optimal-combination-therapy-for-overactive-bladder
#9
Jerry Di Salvo, Hiroshi Nagabukuro, Alexandra Wickham, Catherine Abbadie, Julie A DeMartino, Aileen Fitzmaurice, Loise Gichuru, Alison Kulick, Marcie J Donnelly, Nina Jochnowitz, Amanda Hurley, Antonio Pereira, Anthony Sanfiz, Gregory Veronin, Katherine Villa, John Woods, Beata Zamlynny, Emanuel Zycband, Gino M Salituro, Tara Frenkl, Ann E Weber, Scott D Edmondson, Mary Struthers
Although the physiological role of muscarinic receptors in bladder function and the therapeutic efficacy of muscarinic antagonists for the treatment of overactive bladder are well established, the role of β3-adrenergic receptors (β3ARs) and their potential as therapeutics is just emerging. In this manuscript, we characterized the pharmacology of a novel β3AR agonist vibegron (MK-4618, KRP-114V) and explored mechanistic interactions of β3AR agonism and muscarinic antagonism in urinary bladder function. Vibegron is a potent, selective full β3AR agonist across species and it dose-dependently increased bladder capacity, decreased micturition pressure and increased bladder compliance in rhesus monkeys...
December 13, 2016: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/27958220/efficacy-and-safety-of-medium-to-long-term-use-of-tolterodine-extended-release-with-or-without-tamsulosin-in-patients-with-benign-prostate-hyperplasia-and-larger-prostate-size-a-double-blind-placebo-controlled-randomized-clinical-trial
#10
RANDOMIZED CONTROLLED TRIAL
Jian-Liang Cai, Zhe Zhou, Yan Yang, Yi-Fu Yan, Shuo Jing, Yan-Qun Na
BACKGROUND: The medium-to-long-term use of antimuscarinics alone or in combination with an α-blocker in men with an enlarged prostate is still controversial. This double-blind, placebo-controlled, randomized clinical trial aimed to investigate the efficacy and safety of medium-to-long-term use of tolterodine extended release (ER) with or without tamsulosin in patients with benign prostate hyperplasia (BPH) and larger prostate size. METHODS: Totally, 152 patients (age ≥50 years) with BPH, International Prostate Symptom Score (IPSS) ≥12, quality-of-life (QoL) score ≥3, and total prostate volume ≥25 ml were enrolled in this study...
December 20, 2016: Chinese Medical Journal
https://www.readbyqxmd.com/read/27935011/electrical-stimulation-with-non-implanted-electrodes-for-overactive-bladder-in-adults
#11
REVIEW
Fiona Stewart, Luis F Gameiro, Regina El Dib, Monica O Gameiro, Anil Kapoor, Joao L Amaro
BACKGROUND: Several options exist for managing overactive bladder (OAB), including electrical stimulation (ES) with non-implanted devices, conservative treatment and drugs. Electrical stimulation with non-implanted devices aims to inhibit contractions of the detrusor muscle, potentially reducing urinary frequency and urgency. OBJECTIVES: To assess the effects of ES with non-implanted electrodes for OAB, with or without urgency urinary incontinence, compared with: placebo or any other active treatment; ES added to another intervention compared with the other intervention alone; different methods of ES compared with each other...
December 9, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27878051/anticholinergics-for-overactive-bladder-temporal-trends-in-prescription-and-treatment-persistence
#12
Christopher J D Wallis, Colin Lundeen, Nicole Golda, Hilary Brotherhood, Peter Pommerville, Lesley Carr
INTRODUCTION: We sought to understand the contemporary pharmacologic management of overactive bladder (OAB) in a single-payer system. We examined temporal trends in the use of anticholinergic medications and assessed whether the likelihood of patients changing their anticholinergic therapy was predicted by their current therapy. METHODS: We conducted a retrospective, population-based analysis of prescription records from the PharmaNet database in BC, Canada. We identified patients treated with one or more anticholinergic prescriptions between 2001 and 2009...
August 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/27829538/pharmacokinetic-drug-interaction-study-between-overactive-bladder-drugs-mirabegron-and-tolterodine-in-japanese-healthy-postmenopausal-females
#13
Yuki Nomura, Hiromi Iitsuka, Junko Toyoshima, Kentaro Kuroishi, Toshifumi Hatta, Atsunori Kaibara, Masataka Katashima, Selina Moy, Taiji Sawamoto
Mirabegron, the first selective β3-adrenoceptor agonist for the treatment of overactive bladder (OAB), inhibits cytochrome P450 isozyme CYP2D6. This study was performed in Japanese healthy postmenopausal female volunteers to assess any pharmacokinetic drug interaction between mirabegron and tolterodine, another OAB drug and a sensitive substrate of CYP2D6. Tolterodine 4 mg was orally administered from Days 1-7 and co-administered with mirabegron 50 mg from Days 8-14. Mirabegron 50 mg increased maximum concentration (Cmax) and area under the concentration-time curve from zero to 24 h after dosing (AUC24h) of tolterodine by 2...
December 2016: Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/27789373/design-of-hydrogels-of-5-hydroxymethyl-tolterodine-and-their-studies-on-pharmacokinetics-pharmacodynamics-and-transdermal-mechanism
#14
Wenhua Liu, Lirong Teng, Kongtong Yu, Xiangshi Sun, Chunyu Fan, Chaoxing Long, Na Liu, Shuang Li, Bing Wu, Qingji Xu, Fengying Sun, Youxin Li
development, single-factor experiments were employed to evaluate the effect of adding different matrix, enhancers, 5-HMT, ethanol and glycerol on drug skin development, single-factor experiments were employed to evaluate the effect of adding different matrix, enhancers, 5-HMT, ethanol and glycerol on drug skin permeation. Finally, Carbopol 940 was selected as the gel matrix with N-methyl pyrrolidone (NMP) chosen as the enhancer. The relationship between time and the steady accumulative percutaneous amount (Q, μgcm(-2)) of optimized 5-HMT hydrogels was Q4-12h=1290...
January 1, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/27738922/a-short-review-of-drug-food-interactions-of-medicines-treating-overactive-bladder-syndrome
#15
Paweł Paśko, Tomasz Rodacki, Renata Domagała-Rodacka, Danuta Owczarek
Background Overactive bladder syndrome is a condition where one or more of the symptoms such as pollakiuria, urgent need to urinate, nocturia and urinary incontinence is observed. Its prevalence ranges between 7 and 27 % in men and 9-43 % in women. The role of a pharmacist is to educate the patient on medications administration scheme, and drug interactions with particular food or food components. Aim of the review To assess a potential impact of food and fruit juice on the pharmacokinetic and therapeutic effects of medications used in treating overactive bladder syndrome...
December 2016: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/27695293/application-of-physiologically-based-pharmacokinetic-modeling-in-predicting-drug-drug-interactions-for-sarpogrelate-hydrochloride-in-humans
#16
Jee Sun Min, Doyun Kim, Jung Bae Park, Hyunjin Heo, Soo Hyeon Bae, Jae Hong Seo, Euichaul Oh, Soo Kyung Bae
BACKGROUND: Evaluating the potential risk of metabolic drug-drug interactions (DDIs) is clinically important. OBJECTIVE: To develop a physiologically based pharmacokinetic (PBPK) model for sarpogrelate hydrochloride and its active metabolite, (R,S)-1-{2-[2-(3-methoxyphenyl)ethyl]-phenoxy}-3-(dimethylamino)-2-propanol (M-1), in order to predict DDIs between sarpogrelate and the clinically relevant cytochrome P450 (CYP) 2D6 substrates, metoprolol, desipramine, dextromethorphan, imipramine, and tolterodine...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27681701/antimuscarinic-medication-use-in-elderly-patients-with-overactive-bladder
#17
Nandita Kachru, Sneha Sura, Satabdi Chatterjee, Rajender R Aparasu
BACKGROUND: Antimuscarinic medications are the first-line pharmacological treatment for overactive bladder (OAB); however, little is known about the utilization pattern of antimuscarinic agents in elderly patients with OAB. OBJECTIVE: This study examined the prevalence and predictors of antimuscarinic medication prescribing in elderly patients with OAB, using national ambulatory survey data. METHODS: This cross-sectional study utilized the 2009-2010 National Ambulatory Medical Care Survey and the outpatient component of the National Hospital Ambulatory Medical Care Survey...
October 2016: Drugs & Aging
https://www.readbyqxmd.com/read/27678410/differential-effects-of-the-enantiomers-of-tamsulosin-and-tolterodine-on-p-glycoprotein-and-cytochrome-p450-3a4
#18
COMPARATIVE STUDY
Aneta Doricakova, Dirk Theile, Johanna Weiss, Radim Vrzal
The pregnane X receptor (PXR) is a transcription factor regulating P-glycoprotein (P-gp; ABCB1)-mediated transport and cytochrome P450 3A4 (CYP3A4)-mediated metabolism of xenobiotics thereby affecting the pharmacokinetics of many drugs and potentially modulating clinical efficacy. Thus, pharmacokinetic drug-drug interactions can arise from PXR activation. Here, we examined whether the selective α1-adrenoreceptor blocker tamsulosin or the antagonist of muscarinic receptors tolterodine affect PXR-mediated regulation of CYP3A4 and of P-gp at the messenger RNA (mRNA) and protein level in an enantiomer-specific way...
January 2017: Naunyn-Schmiedeberg's Archives of Pharmacology
https://www.readbyqxmd.com/read/27589789/tolterodine-tartrate-proniosomal-gel-transdermal-delivery-for-overactive-bladder
#19
Rajan Rajabalaya, Guok Leen, Jestin Chellian, Srikumar Chakravarthi, Sheba R David
The goal of this study was to formulate and evaluate side effects of transdermal delivery of proniosomal gel compared to oral tolterodine tartrate (TT) for the treatment of overactive bladder (OAB). Proniosomal gels are surfactants, lipids and soy lecithin, prepared by coacervation phase separation. Formulations were analyzed for drug entrapment efficiency (EE), vesicle size, surface morphology, attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, in vitro skin permeation, and in vivo effects...
August 31, 2016: Pharmaceutics
https://www.readbyqxmd.com/read/27579830/estimated-budget-impact-of-increased-use-of-mirabegron-a-novel-treatment-for-overactive-bladder
#20
Sinem Perk, Ronald C Wielage, Noll L Campbell, Timothy M Klein, Anthony Perkins, Linda M Posta, Thomas Yuran, Robert W Klein, Daniel B Ng
BACKGROUND: Oral pharmacological treatment for overactive bladder (OAB) consists of antimuscarinics and the beta-3 adrenergic agonist mirabegron. Antimuscarinic adverse events (AEs) such as dry mouth, constipation, and blurry vision can result in frequent treatment discontinuation rates, leaving part of the OAB population untreated. Antimuscarinics also contribute to a patient's anticholinergic cognitive burden (ACB), so the Beers Criteria recommends cautious use of antimuscarinics in elderly patients who take multiple anticholinergic medications or have cognitive impairment...
September 2016: Journal of Managed Care & Specialty Pharmacy
keyword
keyword
100353
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"